HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren Dubinsky that outlined FDA clearances and approvals across the medical device sector. HeartBeam’s 12-lead electrocardiogram synthesis software was cleared Dec. 8 to assess arrhythmias by converting heart signal data captured from 3 dimensions using the company’s portable, non-invasive recorder into a standard 12-lead ECG format suitable for remote clinical review.
HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated in PatentVest’s “Total Cardiac Intelligence” report, according to an InvestorBrandNetwork report. The ranking reflects the strength of its intellectual-property foundation, with 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, underscoring the company’s growing influence in next-generation remote cardiac monitoring.
Questions around this news
What was the FDA clearance described in the release?
The release says the FDA cleared HeartBeam’s 12-lead ECG synthesis software on Dec. 8 to assess arrhythmias. The software converts cardiac signals gathered in three dimensions by the company’s portable, non-invasive recorder into a conventional 12-lead ECG format for clinicians to review remotely.
How does the portable cardiac technology described in the release work?
The release describes a cable-free device that gathers ECG signals from three non-coplanar directions. Its software synthesizes those signals into a 12-lead ECG, which is intended to support clinical review when a patient is outside a medical facility. The release also says the technology is designed for portable use.
What is a 12-lead ECG?
An electrocardiogram, or ECG, records electrical activity associated with the heart. A 12-lead ECG presents that activity from multiple electrical viewpoints, helping clinicians examine patterns that may be relevant to heart rhythm and other cardiac concerns. The term “lead” refers to a view derived from electrodes, not necessarily to a separate physical wire.
How does FDA clearance differ from FDA approval?
In general, clearance and approval are distinct regulatory pathways for medical devices. Clearance commonly applies to devices reviewed through a process comparing them with an appropriate legally marketed device; approval generally follows a more extensive review of evidence for safety and effectiveness. Which pathway applies depends on the device and its regulatory classification.
To learn more about Heartbeam’s Portable ECG Technology, visit https://ibn.fm/pfPB1
About HeartBeam, Inc.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement. For additional information, visit .
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- HeartBeam, Inc.
- Ticker
- NASDAQ: BEAT
- Announcement
- Regulatory
Key figures
- PatentVest ranking
- second worldwide
- Companies evaluated
- 243
- Global patent publications
- 82
- Patent families
- 15
- Issued patents
- over 20
Products and programs
SEC filings
Earlier from HeartBeam, Inc.
- HeartBeam (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation
- HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal
- HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
- HeartBeam (NASDAQ: BEAT) Reports Q3 2025 Results as FDA Review Nears Completion and Commercial Readiness Accelerates
